Q1 Earnings Forecast for Medpace Issued By Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Medpace in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Cherny forecasts that the company will post earnings of $3.03 per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace’s Q2 2025 earnings at $2.96 EPS, Q3 2025 earnings at $2.92 EPS, Q4 2025 earnings at $3.16 EPS, FY2025 earnings at $12.07 EPS, FY2026 earnings at $12.76 EPS, FY2027 earnings at $13.90 EPS and FY2028 earnings at $15.81 EPS.

A number of other analysts have also commented on MEDP. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday. They issued a “market perform” rating and a $330.00 price objective on the stock. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $376.30.

Medpace Stock Performance

Shares of Medpace stock opened at $324.51 on Wednesday. The firm has a market cap of $9.89 billion, a PE ratio of 25.69, a P/E/G ratio of 3.81 and a beta of 1.47. The business’s 50 day simple moving average is $337.16 and its 200 day simple moving average is $339.57. Medpace has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently modified their holdings of the stock. R Squared Ltd bought a new stake in shares of Medpace during the 4th quarter worth about $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Medpace during the fourth quarter worth approximately $31,000. Stone House Investment Management LLC acquired a new position in shares of Medpace in the third quarter valued at approximately $33,000. Jones Financial Companies Lllp increased its stake in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the period. Finally, Lindbrook Capital LLC boosted its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.